Table 2 Demographic and clinical characteristics of NMOSD with and without CTD
From: Neuromyelitis optica spectrum disorders with and without connective tissue disorders
NMOSD (39) | NMOSD with CTD (18) | P | |
|---|---|---|---|
Gender, n (% female) | 37 (94.9%) | 18 (100%) | 0.839 |
Age at onset, years | 39.97 ± 13.82 | 42.33 ± 11.29 | 0.530 |
Follow-up duration, years | 5.63 ± 4.63 | 5.04 ± 3.83 | 0.641 |
Annualized relapse rate (ARR) | 0.98 ± 0.54 | 1.40 ± 1.51 | 0.127 |
ARR before regular medication | 1.58 ± 2.18 | 1.66 ± 1.44 | 0.899 |
ARR after regular medication | 0.64 ± 0.79 | 1.39 ± 1.96 | 0.100 |
Number of attacks | 3.97 ± 2.07 | 4.28 ± 2.32 | 0.623 |
Neuropathic pain, n (%) | 21 (53.8%) | 10 (55.6%) | 0.904 |
EDSS at nadir | 3.5 (1, 8) | 4 (1.5, 8.5) | 0.031* |
Visual functions | 0 (0, 6) | 1 (0, 6) | 0.139 |
Pyramidal functions | 1 (0, 4) | 2 (0, 4) | 0.219 |
Sensory functions | 2 (0, 4) | 3 (0, 4) | 0.007* |
Bowel and bladder | 0 (0, 5) | 3 (0, 5) | 0.256 |
EDSS at last follow-up | 2 (1, 8) | 2.5 (1.5, 8.5) | 0.403 |
Visual functions | 0 (0, 4) | 1 (0, 6) | 0.111 |
Pyramidal functions | 1 (0, 4) | 1 (0, 4) | 0.595 |
Sensory functions | 1 (0, 4) | 2 (0, 4) | 0.063 |
Bowel and bladder | 0 (0, 5) | 0 (0, 5) | 0.856 |
Initial presentation, n (%) | |||
ON | 14 (35.9%) | 6 (33.3%) | 0.850 |
Area postrema syndrome | 8 (20.5%) | 2 (11.1%) | 0.622 |
AM | 15 (38.5%) | 9 (50.0%) | 0.412 |
Others | 2 (5.1%) | 1 (5.6%) | 1.000 |